Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity

M Rosás-Umbert, JD Gunst, MH Pahus… - Nature …, 2022 - nature.com
In simian-human immunodeficiency virus (SHIV)-infected non-human primates, broadly
neutralizing antibodies (bNAbs) against the virus appear to stimulate T cell immunity. To …

Post-immune antibodies in HIV-1 infection in the context of vaccine development: a variety of biological functions and catalytic activities

A Timofeeva, S Sedykh, G Nevinsky - Vaccines, 2022 - mdpi.com
Unlike many other viruses, HIV-1 is highly variable. The structure of the viral envelope
changes as the infection progresses and is one of the biggest obstacles in developing an …

Potent induction of envelope-specific antibody responses by virus-like particle immunogens based on HIV-1 envelopes from patients with early broadly neutralizing …

C Beltran-Pavez, I Bontjer, N Gonzalez… - Journal of …, 2022 - Am Soc Microbiol
Longitudinal studies in HIV-1-infected individuals have indicated that 2 to 3 years of infection
are required to develop broadly neutralizing antibodies. However, we have previously …

High-throughput B cell epitope determination by next-generation sequencing

LM Walker, AR Shiakolas, R Venkat, ZA Liu… - Frontiers in …, 2022 - frontiersin.org
Development of novel technologies for the discovery of human monoclonal antibodies has
proven invaluable in the fight against infectious diseases. Among the diverse antibody …

Vertical HIV-1 transmission in the setting of maternal broad and potent antibody responses

JJ Tu, A Kumar, EE Giorgi, J Eudailey… - Journal of …, 2022 - Am Soc Microbiol
Despite the worldwide availability of antiretroviral therapy (ART), approximately 150,000
pediatric HIV infections continue to occur annually. ART can dramatically reduce HIV mother …

Double and Triple Combinations of Broadly Neutralizing Antibodies Provide Efficient Neutralization of All HIV-1 Strains from the Global Panel

EA Kochina, FA Urusov, AA Kruglov, DV Glazkova… - Viruses, 2022 - mdpi.com
The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1
treatment. In this work, we evaluate the neutralizing activity of the following HIV-1 bNAbs …

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

JF Rosengarten, S Schatz, J Stitz - JoVE (Journal of Visualized …, 2022 - jove.com
The virus-like particle (VLP) capture assay is an immunoprecipitation method, commonly
known as a'pull-down assay'used to purify and isolate antigen-displaying VLPs. Surface …

Commonly elicited antibodies against the base of the HIV-1 Env trimer guide the population-level evolution of a structure-regulating region in gp41

RA Rojas Chávez, D Boyt, N Schwery, C Han… - Journal of …, 2022 - Am Soc Microbiol
The antibody response against the HIV-1 envelope glycoproteins (Envs) guides evolution of
this protein within each host. Whether antibodies with similar target specificities are elicited …

Distinct antibody profiles in HLA-B∗ 57+, HLA-B∗ 57− HIV controllers and chronic progressors

J Klingler, N Paul, G Laumond, S Schmidt, LM Mayr… - AIDS, 2022 - journals.lww.com
Objective: Spontaneous control of HIV replication without treatment in HIV-1 controllers
(HICs) was associated with the development of an efficient T-cell response. In addition …

Host Factors Are Principally Responsible for Natural Resistance to Simian Immunodeficiency Virus Infection in Baboons

AR Mannino - 2022 - search.proquest.com
Human immunodeficiency virus (HIV) originated when certain strains of naturally occurring
simian immunodeficiency virus (SIV) crossed species from nonhuman primates (NHP) to …